www.melanexjou.fora.pl

[px231858]

Chongqing Pharmaceutical behind General Group Reorganisation


Dikang missed appointments were driven back, GM takeover battle riding a tiger

general reorganization of Chongqing Medical Group Four behind

Chuandi Kang Industry Holding Group (DICON Group) fight off a number of competitors Chongqing Pharmaceutical reorganization is no longer news, but in the time of this writing, China General Technology Group (Universal Group), a subsidiary of China General Medicine Holdings Limited (General Medical Control) is a digital high-level Chongqing, Chongqing Pharmaceutical Co., Ltd. re-negotiate (the Chongqing Medicine) matters, seems to have a winner. That being so, can attest to the fact - Chongqing Medical restructuring has changed! But why has changed, began when, in the pharmaceutical industry is still relatively unknown in the general health control, and why so eager to embrace in the arms of Chongqing Medical? These, all the industry attention.



restructuring has changed as a pharmaceutical commercial enterprises, including the main business of Chongqing pharmaceutical pharmaceutical net sales and chain pharmacies, and its purpose is to seek to reorganize as a large plate. In this chain pharmacy business, pharmacy chains in recent years coupled with intense price competition in the high rent, the company's pharmacy chain under the profit situation of the peace in Chongqing is not good, even to the total weight of the first pure marketing business. It is reported that Chongqing Pharmaceutical sales fell last year the total more than thirty percent, the gross profit from the original 35% to 20 ~ 25%. Therefore, funds are urgently needed medicine into the Chongqing to respond to competitive pressures.

the other hand, at the local, Chongqing Medical's main rival is the Taiji Group, both in the commercial strength of the par between the local, but last year's situation, obviously not as good as the development of Chongqing Taiji medicine. Therefore, Chongqing Medical seeking our strength, to break this passive situation must be selected to introduce capital. To this end, it has worked with China Resources, Founder, Shanghai Fuxing nationwide, more than 20 large enterprise groups to increase their investment turns to negotiate and eventually hit it off with DICON Group, the two sides signed an agreement late last year, 4.91 yuan per share Dikang Group the price of 3816 million capital increase, the total capital increase amounting to 187 million, accounting for the total share capital of Chongqing Medical 43.07%, becoming its largest shareholder, the parties have agreed a one-time payment, payment for a period not exceeding six months. Chongqing Pharmaceutical Group of the White Dikang intended to peace pharmacies, DICON side has claimed that two or three years, the development of 2,000 peace pharmacies Jiangzai, the annual sales income of 50 billion yuan. But still have not seen Dikang Chongqing Pharmaceutical Group once again makes available funds into passive.
32477 | 48
fact, DICON Group not only poor performance last year, it's just recently came into the market less than six months in Chongqing, Chongqing Dikang Stores Co., Ltd., another shareholder - Chengshang For the spin by way of equity swap news. It is reported that, due to unfavorable operating conditions, plus an annual 33 million yuan Dikang department store share of the rent and the annual opening of the six million yuan spent on the renovation of the heavy financial pressure, at the end of the year, Chongqing Dikang there have been significant losses of department stores, a move on the financial situation is not ideal Dikang this is undoubtedly worse. Another group affiliated enterprises Dikang Dikang medicine last year, although the report did not come out, but the first three quarters of net profit fell 42% basically reflects the fact that its full-year net profit is not optimistic. Thus, there is a large amount of Dikang Group-flow problem, which is the delay or medicine for the replenishment of hiding something in Chongqing.

new buyers involved tombo corporation with a set of sharp weight management weight management group of doctors in Chongqing after drug screen line.

at the time of this writing, general health control and several other corporate executives are now in Chongqing, Chongqing, and the reorganization of the local parties to negotiate medical matters, as the first media interview about the matter of the general reorganization Vice President of Medical Control GUO Yi is not in charge of the city to negotiate matters In fact, the General Hospital of Chongqing Medical sides have re-charged about two years, beginning in Chongqing pharmaceutical not enthusiastic, they focus groups into the DICON body, but in the Di Hong Group to deliver into the injection period and can not promise, Chongqing became positive in spite of medicine, if the final success of the reorganization, General Medical control must be to Chongqing Pharmaceutical Holdings, probably need more than 100 million yuan to be holding 51% stake in Chongqing Medicine , not more. Present the facts, because Dikang Group is unable to perform within the time agreed upon funding commitments, and Chongqing Medicine can not slow down the pace of restructuring, so Chongqing Pharmaceutical Group to Dikang exit, turn in close communication with the general health control. Chongqing Pharmaceutical

general reorganization, the same value of its pharmaceutical retail market in the country's number one peace pharmacies. Chongqing Pharmaceutical sales of 4.5 billion last year, its overall plan is out of the west, by three to five years and strive to achieve annual sales revenue exceeded billion target. March 30, Chongqing Mayor Wang Hongju met with the GM Group Chairman Chen Wei-kan and his party to strengthen strategic cooperation and promote common development of friendly conversation. Indications that the general reorganization of Chongqing Medical likely, from the re-side the information back to the author's view, Chongqing Medical restructuring, exit Dikang Group, General Hospital took over control of the

then, Chongqing Medical Group of missed appointments later in the DICON Why so eager to find new On the one hand, as a pharmaceutical commercial enterprises nationwide, However, the capital of Chongqing has become a stumbling block to expansion of medicine - even though the total assets of Chongqing Medical up to 8 billion, but capital is only 50.44 million yuan, according to state regulations, business investment since the investment part of the project can not exceed the Enterprise Capital 50%, that is, if the investment in Chongqing pharmaceutical, part of its own funds can not be more than 25.22 million yuan. Therefore, the national pharmaceutical market in Chongqing pharmaceutical strategies compete severely restricted, to seek capital to become an important way to pursue development of the operation. On the other hand, the two have appeared in Chongqing, the local state-owned pharmaceutical companies, the reorganization of success and failure cases, one is southwest of medicine, because the slow pace of restructuring, and finally become a government-led , in fact Chongqing Pharmaceutical certainly do not want to become a To put it more to understand that, let Chongqing pharmaceutical concern is that if the restructuring was shelved, the Chongqing municipal government is likely to allow competitors to intervene Taiji Group, which is obviously Chongqing Pharmaceutical want to see. Why they change from passive to active, to reach out to other capital, but also want to test this Dikang attitudes.



GM takeover battle riding a tiger in the pharmaceutical industry is still relatively new to the general group as early as a few years ago, began to penetrate the pharmaceutical industry to develop Biomedical Corporation, the company is mainly engaged in high-tech intellectual property research and development of pharmaceutical products; 2001 Hainan Alliance Pharmaceutical Holdings Limited, the registered capital to 1.8 billion, the company is mainly engaged in genetic engineering drugs, biochemical drugs and other drug research and development, production and sales; the same year, holding Hainan Pharmaceutical Co., Ltd. Sanyo Delin, the registered capital increased to 110 million yuan, the company is mainly engaged in antibiotic-resistant products such as enzymes and efficient development, production and sales; In 2002, the Group 2 billion investment in the establishment of Perfect Pharmaceutical Co., Ltd., the company is mainly engaged in production and development of Chinese medicine products.

general group as the current directly under SASAC's 177 key enterprises, import and export business is based enterprises, the end of 2003 the total assets of nearly 200 billion yuan. The group earlier reported the overall reform program, the SASAC, the main content of which is to the pharmaceutical industry as one of three main business groups, the end of time has been approved by the SASAC. SASAC Director Li Rongrong, according to the speech, if not the main business of the industry's top few, it will be forced reorganization, merger situation. In fact, the enterprises directly under SASAC has been reduced in recent years, a lot of planning by the SASAC, the last of its key enterprises directly under the control of seventy to eighty or so, so maybe it still lost nearly home. In this context, Shanghai GM group pressure is very great. In fact, after the establishment of universal health control,[link widoczny dla zalogowanych], it has already talked about a lot of acquisitions, including Jahwa, Nanjing Medicine, Tianjin Medical, Shandong and Shaanxi, Xinhua, a pharmaceutical company, etc., in which an, Shaanxi, Shandong Xinhua Pharmaceutical Company and negotiations have fail, Jahwa being discussed, Nanjing Pharmaceutical inconclusive, Tianjin Medical recently a conclusion.

pharmaceutical industry and GM Group's strategic development goals through: acquisition of a considerable scale by investing in large-scale pharmaceutical group as a domestic pharmaceutical industry platform on which to complete the transformation of the Group's strategic cross-sectoral team of professionals and professional construction, and lay groups as soon as the status of the pharmaceutical industry sectors, and to elevate the scale of the pharmaceutical industry, profits and other business indicators in the Group's share of the three core businesses; higher profitability by investing in mergers and acquisitions of small and medium pharmaceutical companies, to ensure that the Group rapid development in the pharmaceutical industry, the asset value of preservation goals; high-tech intellectual property rights by increasing the variety of new drugs and technology development, foster innovation projects for the Group's sustainable growth in the pharmaceutical industry to provide strong support and protection. At present, the latter two are already in progress, the acquisition of several pharmaceutical companies, but has not yet achieved the acquisition of large pharmaceutical groups, so dishes do not large, the top few from the industry is still relatively far from the target.

can say, General Medical Group opened later in the takeover battle has been difficult to recover, showing the Chancery of the state. However, as the group not familiar with the pharmaceutical industry, medicine, business progress fast enough, in the M & A projects have already spoken about the medicine, some could have been the opportunity to win in the end is not won on the one hand is the group asking for too much, such as large investment projects require more than 10% return on investment, small investment requires higher rates of return, the current M & A projects meet the requirements of this few, which is equal to the hands and feet tied to their living. The other hand, many large pharmaceutical companies doing well, its not willing to increase their investment or sell. Thus, although GM said the investment group is not a problem, but still can not quickly achieve text text

text